Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 5, 2014, Pages 637-644

  Franco, Valentina ^a   Iudice, Alfonso ^b   Grillo, Elisabetta ^c   Citraro, Rita ^d   De Sarro, Giovambattista ^d   Russo, Emilio ^d  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Epilepsy; Intravenous carbamazepine; Perampanel; Secondarily generalized seizures

Indexed keywords

CARBAMAZEPINE; PERAMPANEL;

DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; PARTIAL ONSET SEIZURE; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARILY GENERALIZED SEIZURE; TONIC CLONIC SEIZURE;

ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; CLINICAL TRIALS, PHASE III AS TOPIC; EPILEPSY, GENERALIZED; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEIZURES; TREATMENT OUTCOME;

EID: 84896266745     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.879572     Document Type: Review

References (36)

1. Panayiotopoulos CP. The new ILAE report on terminology and concepts for organization of epileptic seizures: a clinicians critical view and contribution. Epilepsia 2011;52:2155-60
2. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005;46:470-2
3. Korff CM, Scheffer IE. Epilepsy classification: a cycle of evolution and revolution. Curr Opin Neurol 2013;26:163-7
4. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51:676-85
5. Beydoun A, DSouza J. Treatment of idiopathic generalized epilepsy - a review of the evidence. Expert Opin Pharmacother 2012;13:1283-98
6. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54:551-63
7. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol 2012;11:792-802
8. Neligan A, Shorvon SD. Prognostic factors, morbidity and mortality in tonicclonic status epilepticus: a review. Epilepsy Res 2011;93:1-10
9. Langtry HD, Gillis JC, Davis R. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997;54:752-73
10. Coppola G, Mangano S, Tortorella G, et al. Levetiracetam during 1-year followup in children, adolescents, and young adults with refractory epilepsy. Epilepsy Res 2004;59:35-42
11. Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a doubleblind comparison with phenytoin. Epilepsia 1999;40:601-7
12. Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010;51:958-67
13. Russo E, Gitto R, Citraro R, et al. New AMPA antagonists in epilepsy. Expert Opin Investig Drugs 2012;21:1371-89
14. Franco V, Crema F, Iudice A, et al. Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res 2013;70:35-40
15. Krauss GL, Perucca E, Ben-Menachem E, et al. Perampanel, a selective, noncompetitive alpha-amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia 2013;54:126-34
16. French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013;54:117-25
17. French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012;79:589-96
18. Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78:1408-15
19. Ko D, Ramsay RE. Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures. Acta Neurol Scand Suppl 2013;127:36-43
20. Steinhoff BJ, Ben-Menachem E, Ryvlin P, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia 2013;54:1481-9
21. Leppik IE, Hovinga CA. Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediaterelease formulations. Epilepsia 2013;54:28-35
22. Loscher W, Honack D, Richter A, et al. New injectable aqueous carbamazepine solution through complexing with 2- hydroxypropyl-beta- cyclodextrin: tolerability and pharmacokinetics after intravenous injection in comparison to a glycofurol-based formulation. Epilepsia 1995;36:255-61
23. Perioli L, Pagano C. Inorganic matrices: an answer to low drug solubility problem. Expert Opin Drug Deliv 2012;9:1559-72
24. Williams HD, Trevaskis NL, Charman SA, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev 2013;65:315-499
25. Brewster ME, Anderson WR, Estes KS, Bodor N. Development of aqueous parenteral formulations for carbamazepine through the use of modified cyclodextrins. J Pharm Sci 1991;80:380-3
26. Brewster ME, Anderson WR, Meinsma D, et al. Intravenous and oral pharmacokinetic evaluation of a 2- hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions. J Pharm Sci 1997;86:335-9
27. Loscher W, Honack D. Intravenous carbamazepine: comparison of different parenteral formulations in a mouse model of convulsive status epilepticus. Epilepsia 1997;38:106-13
28. Miller JM, Dahan A. Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: model validation. Int J Pharm 2012;430:388-91
29. Cloyd JC, Marino S, Birnbaum AK. Factors affecting antiepileptic drug pharmacokinetics in community-dwelling elderly. Int Rev Neurobiol 2007;81: 201-10
30. Conway JM, White JR, Birnbaum AK, et al. Safety of an IV formulation of carbamazepine. Epilepsy Res 2009;84: 242-4
31. Marino SE, Birnbaum AK, Leppik IE, et al. Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin Pharmacol Ther 2012;91:483-8
32. Ahmed GF, Brundage RC, Marino SE, et al. Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy. J Clin Pharmacol 2013;53:276-84
33. Jain AS, Date AA, Pissurlenkar RR, et al. Sulfobutyl ether(7) beta-cyclodextrin (SBE(7) beta-CD) carbamazepine complex: preparation, characterization, molecular modeling, and evaluation of in vivo anti-epileptic activity. AAPS PharmSciTech 2011;12:1163-75
34. Kelmann RG, Kuminek G, Teixeira HF, Koester LS. Carbamazepine parenteral nanoemulsions prepared by spontaneous emulsification process. Int J Pharm 2007;342:231-9
35. Madhusudhan B, Rambhau D, Apte SS, Gopinath D. 1-O-alkylglycerol stabilized carbamazepine intravenous o/w nanoemulsions for drug targeting in mice. J Drug Target 2007;15:154-61
36. Citraro R, Aiello R, Franco V, et al. New AMPA antagonists in Epilepsy. Targeting alpha-amino-3-hydroxyl-5- methyl-4-isoxazole-propionate receptors in epilepsy 2014; In press